Rimegepant: Difference between revisions
From Pharmacopedia
More actions
| [unchecked revision] | [checked revision] |
MDElliottMD (talk | contribs) Category taxonomy ship: retag Migraine Medicines -> Antimigraine agents |
MDElliottMD (talk | contribs) parser-claude: Rimegepant MedTemplate refill, Top 300 stub upgrade |
||
| Line 1: | Line 1: | ||
{{MedTemplate | {{MedTemplate | ||
| generic | | generic = Rimegepant | ||
| brand | | brand = Nurtec ODT | ||
| structure | | structure = | ||
| classes | | classes = [[:Category:Gepants|Gepant (small-molecule CGRP receptor antagonist)]], [[:Category:Antimigraine medicines|Antimigraine medicine]], [[:Category:Analgesics|Analgesic]] | ||
| | | uses = <vote slug="acute-migraine-use">Acute migraine with or without aura (FDA, 2020)</vote>, <vote slug="migraine-prophylaxis-use">Migraine preventive treatment (FDA, 2021; '''the first medicine with both acute and preventive migraine indications''')</vote> | ||
| uses | | starting_dose = Acute migraine: 75 mg PO at onset, maximum one dose per 24 hours. Preventive: 75 mg PO every other day | ||
| starting_dose | | preparations = Orally disintegrating tablet 75 mg | ||
| preparations | | fda_max = 75 mg per dose; one dose per 24 hours (acute); one dose every other day (preventive) | ||
| fda_max = | | pill_id = | ||
| routes | | routes = Oral (sublingual disintegration) | ||
| onset | | onset = 1-2 hours for migraine relief | ||
| duration | | duration = ~48 hours of headache freedom | ||
| halflife | | halflife = ~11 hours<ref name="nurtec-label">FDA Prescribing Information, Nurtec ODT (rimegepant), Biohaven/Pfizer, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212728s003lbl.pdf</ref> | ||
| bioavailability = ~64% (oral)<ref name="nurtec-label" /> | |||
| pregnancy = Limited human data.{{citation needed}} | |||
| legal = [[USLegal:Prescription only|Rx-only]] in US | |||
| | | mechanism = <vote slug="rimegepant-mech-claim">Small-molecule antagonist of the calcitonin gene-related peptide (CGRP) receptor, the first oral CGRP-targeting agent in widespread clinical use. CGRP is the dominant pro-migraine neuropeptide released from trigeminal nerve terminals; blocking its receptor blunts the neurogenic inflammation that drives migraine pain.</vote> '''Unlike triptans, rimegepant does not cause vasoconstriction''' and is safe in patients with coronary artery disease and other vascular conditions where triptans are contraindicated. The dual acute-and-preventive indication is the unique pharmacological feature among migraine medicines. The second-generation gepants (rimegepant, ubrogepant, atogepant) have a clean hepatic-safety profile compared to the first-generation gepants withdrawn during development for hepatotoxicity<ref name="nurtec-label" />. | ||
| | |||
| | |||
| | |||
| | |||
}} | }} | ||
== References == | |||
<references /> | |||
[[Category: | [[Category:Gepants]] | ||
[[Category: | [[Category:Antimigraine medicines]] | ||
[[Category:Analgesics]] | [[Category:Analgesics]] | ||